폐색전증에서 혈전용해

Other Titles
Thrombolysis in Pulmonary Embolism
Authors
최원일
Department
Dept. of Internal Medicine (내과학)
Issue Date
2013
Citation
대한내과학회지, Vol.84(1) : 46-48, 2013
ISSN
1738-9364
Abstract
The standard therapy for acute pulmonary embolism is initiated with heparin. Massive pulmonary embolism (PE) is defined by the presence of cardiogenic shock, persistent arterial hypotension, or both. It is associated with a high risk of in-hospital death, particularly during the first hours after admission. Thrombolysis is recommended in massive PE. Results from a randomized trial suggested that selected patients with evidence of right ventricular dysfunction and a low risk of bleeding may benefit from thrombolysis. In this issue of the Journal, Kim Yang-Ki and colleagues conducted retrospective review of thrombolytic therapy in PE last 6.5 years in a single center. The mortality rate of massive PE (44%) was higher than submassive PE (8%) in patients with thrombolysis. Major bleeding occurred in 3/21 (14%) patients. This signal reminds us “real-world” hazards of thrombolysis is higher than randomized controlled trial. Although massive PE patients need more intensifying therapy to reduce mortality, we should careful assessment of bleeding risk factors before starting thrombolysis. With regard to submassive PE, this study has limitation to assessing the efficacy of thrombolysis. (Korean J Med 2013;84:46-48) Keywords: Pulmonary embolism; Thrombolysis; Bleeding
URI
http://kumel.medlib.dsmc.or.kr/handle/2015.oak/37808
Appears in Collections:
1. Journal Papers (연구논문) > 1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
Keimyung Author(s)
최원일
File in this Item
oak-bbb-00788.pdf(249.68 kB)Download
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE